R in HEOR modelling for HTA submissions: An assessment

This paper discusses the growing importance of R programming language in Health Economics and Outcomes Research (HEOR) modelling, particularly for Health Technology Assessment (HTA) submissions. The authors highlight the advantages of using R over traditional tools like MS Excel or TreeAge. They emphasise R’s ability to enhance transparency, simplify bug tracking, and enable more complex model structures. 

The paper outlines how R can be integrated throughout the entire model development process, from initial decision-making to final reporting. It mentions various R packages specifically designed for HEOR, such as heemod and darthpack, as well as general-purpose packages that support documentation, testing, and reporting. The authors also note using version control systems and AI tools to optimise the modelling process further. 

The adoption of R by HTA agencies is discussed, focusing on NICE (UK) and ZIN (Netherlands). While these agencies are beginning to accept R-based models, the authors acknowledge that widespread adoption is still limited. They highlight NICE’s pilot program using R for a reusable reference model in advanced renal cell carcinoma, demonstrating the potential for R to improve consistency and efficiency in HTA decision-making. 

The paper concludes by emphasising R’s readiness to become the primary tool for health economics modelling. It notes that R’s versatility and large community support make it well-positioned to adapt to future changes in the HTA landscape, such as increased use of AI and potential shifts towards generalised cost-effectiveness modelling. The authors call for stakeholder collaboration to integrate R into the HEOR field fully. They also offer you Parexel’s expertise in developing R-based health economic models across various therapeutic areas.
 

Read the full paper

Return to Insights Center

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Whitepaper

Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Blog

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Blog

U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022

Blog

Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023

Whitepaper

Reimbursement framework for medical devices in India

Mar 7, 2023

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Whitepaper

Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Blog

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Show more